Silence Therapeutics (SLN) Non-Current Deffered Revenue (2019 - 2026)

Silence Therapeutics' Non-Current Deffered Revenue history runs 8 years deep, the most recent figure standing at $55.2 million for Q1 2026.

• In Q1 2026, Non-Current Deffered Revenue rose 3.62% year-over-year to $55.2 million; the TTM figure through Mar 2026 stood at $55.2 million (up 3.62% YoY), while the FY2025 annual figure was $55.5 million, up 7.07% from the prior year.
• Non-Current Deffered Revenue came in at $55.2 million for Q1 2026 at Silence Therapeutics, roughly flat from $55.5 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $74.5 million in Q4 2022 to a low of -$90.0 million in Q1 2022.
• A 5-year average of -$21.6 million and a median of -$72.6 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue tumbled 198.19% in 2023 and soared 176.67% in 2025, its largest moves.
• Silence Therapeutics' Non-Current Deffered Revenue stood at $74.5 million in 2022, then tumbled by 198.19% to -$73.1 million in 2023, then surged by 170.83% to $51.8 million in 2024, then rose by 7.07% to $55.5 million in 2025, then declined by 0.43% to $55.2 million in 2026.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $55.2 million, $55.5 million, and $55.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison